Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study

[1]  H. Deeg,et al.  Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. , 2003, Blood.

[2]  G. Salles,et al.  Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma , 2002, Bone Marrow Transplantation.

[3]  H. Deeg,et al.  Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. , 2002, Blood.

[4]  H. Deeg,et al.  Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  G. McDonald,et al.  Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). , 2002, Seminars in liver disease.

[6]  K. Sullivan,et al.  Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  H. Athanassiou,et al.  Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[8]  E. Estey,et al.  Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia , 2001, American journal of hematology.

[9]  C. Bokemeyer,et al.  A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation , 2001, British Journal of Cancer.

[10]  B. Vikram,et al.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Uberti,et al.  Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation , 2000, Bone Marrow Transplantation.

[12]  T. Gooley,et al.  Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. , 2000, American journal of clinical oncology.

[13]  H. Deeg,et al.  Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. , 2000, Leukemia research.

[14]  R. Capizzi.  The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. , 1999, Seminars in oncology.

[15]  A. Gratwohl,et al.  Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey , 1998, Bone Marrow Transplantation.

[16]  M. Labopin,et al.  Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.

[17]  M. Labopin,et al.  Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Bone marrow transplantation.

[18]  T. Olencki,et al.  Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors , 1997, Cancer.

[19]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[20]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. Appelbaum,et al.  Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Sullivan,et al.  Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. , 1996, Blood.

[23]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[24]  L. Pickle,et al.  Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. , 1991, Bone marrow transplantation.

[25]  R. Storb,et al.  Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. , 1990 .

[26]  K. Sullivan,et al.  Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. , 1989, Bone marrow transplantation.

[27]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Glick,et al.  WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[30]  Pankaj Sharma,et al.  Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.

[31]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[32]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[33]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.